← United States · Coverage record
US · SEC FORM 4
Roivant Sciences Ltd.
ROIV · Nasdaq · CIK 0001635088 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
88 Form 4 transaction lines observed in the same window
42 sales · 46 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 6 additional owner(s) remain in Form 4 evidence.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-09-18 · Gline Matthew.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 39,296,630
- Previous report
- 36,181,548
- Avg daily volume
- 8,877,408
- Days to cover
- 4.4
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-09-18 | Gline Matthew | Purchase (P) | Common Shares | 3,315 | USD 15.07 | USD 49,957 | SEC filing ↗ |
| 2022-11-10 | Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan | Purchase (P) | Common Shares | 4,000,000 | USD 5.00 | USD 20,000,000 | SEC filing ↗ |
| 2022-04-25 | Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan | Purchase (P) | Common Shares | 8,600 | USD 3.91 | USD 33,626 | SEC filing ↗ |
| 2022-04-22 | Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan | Purchase (P) | Common Shares | 31,685 | USD 3.83 | USD 121,354 | SEC filing ↗ |
Form 4 evidence
221 transaction lines in the latest 365-day window; 800 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Epperly Melissa B, | Sale (S) | Common Shares | 17,750 | USD 36.10 | USD 640,861 | SEC filing ↗ |
| 2026-10-01 | Epperly Melissa B, | Option exercise / conversion (M) | Common Shares | 17,750 | USD 4.46 | USD 79,165 | SEC filing ↗ |
| 2026-09-30 | Venker Eric | Sale (S) | Common Shares | 200,000 | USD 36.62 | USD 7,324,000 | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Epperly Melissa B, | Sale (S) | Common Shares | 17,750 | USD 36.10 | USD 640,861 | SEC filing ↗ |
| 2026-10-01 | Epperly Melissa B, | Option exercise / conversion (M) | Common Shares | 17,750 | USD 4.46 | USD 79,165 | SEC filing ↗ |
| 2026-09-30 | Venker Eric | Sale (S) | Common Shares | 200,000 | USD 36.62 | USD 7,324,000 | SEC filing ↗ |
| 2026-09-30 | Venker Eric | Option exercise / conversion (M) | Common Shares | 200,000 | USD 3.85 | USD 770,000 | SEC filing ↗ |
| 2026-09-30 | Torti Frank | Tax withholding (F) | Common Shares | 40,309 | USD 36.57 | USD 1,474,100 | SEC filing ↗ |
| 2026-09-30 | Sukhatme Mayukh | Tax withholding (F) | Common Shares | 46,879 | USD 36.57 | USD 1,714,365 | SEC filing ↗ |
| 2026-09-30 | Gline Matthew | Tax withholding (F) | Common Shares | 76,171 | USD 36.57 | USD 2,785,573 | SEC filing ↗ |
| 2026-09-20 | Pulik Richard | Tax withholding (F) | Common Shares | 2,129 | USD 39.77 | USD 84,670 | SEC filing ↗ |
| 2026-09-20 | Humes Jennifer | Tax withholding (F) | Common Shares | 3,880 | USD 39.77 | USD 154,308 | SEC filing ↗ |
| 2026-09-16 | Oren Ilan | Award / grant (A) | Common Shares | 5,054 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-16 | MOMTAZEE JAMES C | Award / grant (A) | Common Shares | 5,054 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-16 | MANCHESTER KEITH S | Award / grant (A) | Common Shares | 5,054 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-16 | Gold Daniel Allen | Award / grant (A) | Common Shares | 5,054 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-16 | Fitzgerald Meghan | Award / grant (A) | Common Shares | 5,054 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-16 | Epperly Melissa B, | Award / grant (A) | Common Shares | 5,054 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-15 | Fitzgerald Meghan | Sale (S) | Common Shares | 5,112 | USD 39.74 | USD 203,152 | SEC filing ↗ |
| 2026-09-15 | Epperly Melissa B, | Sale (S) | Common Shares | 4,938 | USD 39.74 | USD 196,230 | SEC filing ↗ |
| 2026-09-10 | Oren Ilan | Tax withholding (F) | Common Shares | 2,378 | USD 40.94 | USD 97,355 | SEC filing ↗ |
| 2026-09-10 | MOMTAZEE JAMES C | Tax withholding (F) | Common Shares | 2,905 | USD 40.94 | USD 118,931 | SEC filing ↗ |
| 2026-09-10 | Gold Daniel Allen | Tax withholding (F) | Common Shares | 5,133 | USD 40.94 | USD 210,145 | SEC filing ↗ |
| 2026-09-10 | Fitzgerald Meghan | Tax withholding (F) | Common Shares | 1,743 | USD 40.94 | USD 71,358 | SEC filing ↗ |
| 2026-09-10 | Epperly Melissa B, | Tax withholding (F) | Common Shares | 2,179 | USD 40.94 | USD 89,208 | SEC filing ↗ |
| 2026-09-08 | Fitzgerald Meghan | Sale (S) | Common Shares | 20,000 | USD 39.90 | USD 798,000 | SEC filing ↗ |
| 2026-09-08 | Fitzgerald Meghan | Option exercise / conversion (M) | Common Shares | 20,000 | USD 8.80 | USD 176,000 | SEC filing ↗ |
| 2026-08-28 | Venker Eric | Sale (S) | Common Shares | 200,000 | USD 35.77 | USD 7,153,393 | SEC filing ↗ |
| 2026-08-28 | Venker Eric | Option exercise / conversion (M) | Common Shares | 200,000 | USD 3.85 | USD 770,000 | SEC filing ↗ |
| 2026-08-21 | Sukhatme Mayukh | Sale (S) | Common Shares | 144,756 | USD 36.48 | USD 5,280,699 | SEC filing ↗ |
| 2026-08-21 | Sukhatme Mayukh | Option exercise / conversion (M) | Common Shares | 144,756 | USD 3.85 | USD 557,311 | SEC filing ↗ |
| 2026-08-20 | Venker Eric | Tax withholding (F) | Common Shares | 13,909 | USD 36.84 | USD 512,408 | SEC filing ↗ |
| 2026-08-20 | Pulik Richard | Tax withholding (F) | Common Shares | 5,749 | USD 36.84 | USD 211,793 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ROIV |
| CIK | 0001635088 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 800 transaction lines from 2022-03-07 to 2026-10-01 4 P purchase lines · 295 S sale lines · 501 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.